People · Operator
Named in public records as an officer, director or promoter · active 2009–2025 · Other Technology, Tourism and Travel Services, Biotechnology, Other Energy, Other Health Care
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Nantero Inc | — | Other Technology | Series C | $172.9M | $1.4B | 2012 |
| Flurry, Inc. | — | Other Technology | Series B | $115.7M | $304.6M | 2009 |
| Sugar Bowl Corp | — | Tourism and Travel Services | Series C | $63.0M | $305.0M | 2025 |
| NanoString Technologies Inc | — | Biotechnology | Series B | $53.3M | $6.0M | 2009 |
| FollowAnalytics, Inc. | — | Other Technology | Series A | $34.2M | $45.5M | 2015 |
| Pentalum Technologies Inc. | — | Other Energy | Series A | $11.2M | $58.1M | 2010 |
| Apieron Inc | — | Other Health Care | Series A | $5.9M | $119.6M | 2009 |
| BioFuelBox CORP | — | Other Energy | Series A | $5.2M | $54.9M | 2009 |
| INTEMATIX Corp | — | Other Technology | Seed | $4.0M | $136.3M | 2009 |
Jennifer Fonstad at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jennifer Fonstad on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jennifer Scott Fonstad | 2 | 2 |
| Wende Hutton | 1 | 16 |
| David Martin | 1 | 13 |
| Mark Gorenberg | 1 | 11 |
| Bruce Sachs | 1 | 10 |
| John Rockwell | 1 | 7 |
| Sonja Hoel Perkins | 1 | 7 |
| JACK FUCHS | 1 | 6 |
| Douglas Pepper | 1 | 6 |
| Denis Barrier | 1 | 5 |
| Sonja Perkins | 1 | 4 |
| Gal Israely | 1 | 4 |
| WILLIAM D. YOUNG | 1 | 4 |
| Keval Desai | 1 | 4 |
| Gregg Adkin | 1 | 4 |
| Richard Levin | 1 | 3 |
| Perry Fell | 1 | 3 |
| Michael Raam | 1 | 3 |
| Steve Wood | 1 | 3 |
| Adi Gan | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.